A61P   1/00  \	0	0	4C201	A61P   1/00	16462	òﴱòμΣ	Drugs for disorders of the alimentary tract or the digestive system [7]
A61P   1/00 171 \	1	1	4C201	A61P   1/00	295	ưʪѤǤäơʬवʤΡʣȣߡ	Drugs for disorders of the alimentary tract or the digestive system[7]
A61P   1/02  \	1	1	4C201	A61P   1/02	9488	ޡ㡥եΣ	Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis [7]
A61P   1/04  \	1	1	4C201	A61P   1/04	28641	硤߱ꡤƻ㡥ޡʬޡǴݸޡΣ	for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants [7]
A61P   1/06  \	1	1	4C201	A61P   1/06	628	㡥ʢˡƻͥΣ	Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia [7]
A61P   1/08  \	1	1	4C201	A61P   1/08	3138	ʪ줤ޤǺޡΣ	for nausea, cinetosis or vertigo; Antiemetics [7]
A61P   1/10  \	1	1	4C201	A61P   1/10	2213	˲ޡΣ	Laxatives [7]
A61P   1/12  \	1	1	4C201	A61P   1/12	3592	Σ	Antidiarrhoeals [7]
A61P   1/12 171 \	2	2	4C201	A61P   1/12	140	ưʪѡʣȣߡ	for animals
A61P   1/14  \	1	1	4C201	A61P   1/14	4423	ò¥ʺޡ㡥ǡ¥ʺޡòɡĲ⥬ޡΣ	Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents [7]
A61P   1/16  \	1	1	4C201	A61P   1/16	23135	¡ǹ㡥¡ݸޡӽ¥ʺޡϲޡΣ	for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics [7]
A61P   1/16 101 \	2	2	4C201	A61P   1/16	389	ʣȣߡ	Cholagogues
A61P   1/16 105 \	2	2	4C201	A61P   1/16	340	ϲޡʣȣߡ	Gallstone-dissoluting drugs
A61P   1/18  \	1	1	4C201	A61P   1/18	7122	¡㡥¡ǡΣ	for pancreatic disorders, e.g. pancreatic enzymes [7]
A61P   3/00  \	0	0	4C201	A61P   3/00	14908	շϼμʷա˦դΤΤΣУˡΣ	Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P 7/00) [7]
A61P   3/00 171 \	1	1	4C201	A61P   3/00	639	ưʪѤǤäơʬवʤΡʣȣߡ	for animals, not classified into 3/02 - 3/14
A61P   3/02  \	1	1	4C201	A61P   3/02	4165	ܺޡ㡥ӥߥ󡤥ߥͥΣ	Nutrients, e.g. vitamins, minerals [7]
A61P   3/02 101 \	2	2	4C201	A61P   3/02	536	ӥߥͺޡʣȣߡ	Vitamin supplements
A61P   3/02 102 \	3	3	4C201	A61P   3/02	1338	ӥߥͺޡʣȣߡ	Vitamin A, D supplements
A61P   3/02 104 \	3	3	4C201	A61P   3/02	368	ӥߥͺޡʣȣߡ	Vitamin B supplements
A61P   3/02 105 \	4	4	4C201	A61P   3/02	223	ӥߥ£ͺޡʣȣߡ	Vitamin B1 supplements
A61P   3/02 106 \	4	4	4C201	A61P   3/02	152	ӥߥ£ͺޡʣȣߡ	Vitamin B2 supplements
A61P   3/02 107 \	3	3	4C201	A61P   3/02	406	ӥߥáͺޡʣȣߡ	Vitamin C, P supplements
A61P   3/02 109 \	3	3	4C201	A61P   3/02	482	ӥߥšͺޡʣȣߡ	Vitamin E, K supplements
A61P   3/04  \	1	1	4C201	A61P   3/04	19975	߸Σ	Anorexiants; Antiobesity agents [7]
A61P   3/06  \	1	1	4C201	A61P   3/06	19292	ɼźޡΣ	Antihyperlipidemics [7]
A61P   3/08  \	1	1	4C201	A61P   3/08	4591	륳ۥᥪΤΤΡ¡ۥУˡΣ	for glucose homeostasis (pancreatic hormones A61P 5/48) [7]
A61P   3/10  \	2	2	4C201	A61P   3/10	37560	ɤΤΤΡ㡥Ǣ¼źޡΣ	for hyperglycaemia, e.g. antidiabetics [7]
A61P   3/12  \	1	1	4C201	A61P   3/12	1080	ŲΥۥᥪΤΤΡΣ	for electrolyte homeostasis [7]
A61P   3/14  \	2	2	4C201	A61P   3/14	1970	륷ΥۥᥪΤΤΡʥӥߥģУþۥУ륷ȥ˥УƤ礦ɣУ᥿УˡΣ	for calcium homeostasis (vitamin D A61P 3/02; parathyroid hormones A61P 5/18; calcitonin A61P 5/22; osteoporosis A61P 19/10; bone metastasis A61P 35/04) [7]
A61P   5/00  \	0	0	4C201	A61P   5/00	3812	ʬϼμΣ	Drugs for disorders of the endocrine system [7]
A61P   5/02  \	1	1	4C201	A61P   5/02	319	뾲ۥˤµΤΤΡ㡥ԣңȡǣңȡãңȡǣңȡޥȥΣ	of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin [7]
A61P   5/04  \	2	2	4C201	A61P   5/04	111	뾲ۥγ򸺾ǤޤϤɹΡΣ	for decreasing, blocking or antagonising the activity of the hypothalamic hormones [7]
A61P   5/06  \	1	1	4C201	A61P   5/06	742	ǾեۥˤµΤΤΡΣ	of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH [7]
A61P   5/08  \	2	2	4C201	A61P   5/08	114	ǾΥۥγ򸺾ǤޤϤɹΡΣ	for decreasing, blocking or antagonising the activity of the anterior pituitary hormones [7]
A61P   5/10  \	1	1	4C201	A61P   5/10	455	ǾθեۥˤµΤΤΡ㡥ԣӣȡãԣȡƣӣȡ̣ȡУң̡ǣȡΣ	of the posterior pituitary hormones, e.g. oxytocin, ADH [7]
A61P   5/12  \	2	2	4C201	A61P   5/12	213	ǾΥۥγ򸺾ǤޤϤɹΡΣ	for decreasing, blocking or antagonising the activity of the posterior pituitary hormones [7]
A61P   5/14  \	1	1	4C201	A61P   5/14	3673	þۥˤµΤΤΡΣ	of the thyroid hormones, e.g. T3, T4 [7]
A61P   5/16  \	2	2	4C201	A61P   5/16	456	þۥγ򸺾ǤޤϤɹΡΣ	for decreasing, blocking or antagonising the activity of the thyroid hormones [7]
A61P   5/18  \	1	1	4C201	A61P   5/18	814	þۥˤµΤΤΡΣ	of the parathyroid hormones [7]
A61P   5/20  \	2	2	4C201	A61P   5/20	138	УԣȤγ򸺾ǤޤϤɹΡΣ	for decreasing, blocking or antagonising the activity of PTH [7]
A61P   5/22  \	2	2	4C201	A61P   5/22	28	륷ȥ˥γ򸺾ǤޤϤɹΡΣ	for decreasing, blocking or antagonising the activity of calcitonin [7]
A61P   5/24  \	1	1	4C201	A61P   5/24	1126	ۥˤµΤΤΡΣ	of the sex hormones [7]
A61P   5/26  \	2	2	4C201	A61P   5/26	437	ɥΣ	Androgens [7]
A61P   5/28  \	2	2	4C201	A61P   5/28	496	ɥΣ	Antiandrogens [7]
A61P   5/30  \	2	2	4C201	A61P   5/30	764	ȥΣ	Oestrogens [7]
A61P   5/32  \	2	2	4C201	A61P   5/32	320	ȥΣ	Antioestrogens [7]
A61P   5/34  \	2	2	4C201	A61P   5/34	145	Σ	Gestagens [7]
A61P   5/36  \	2	2	4C201	A61P   5/36	92	Σ	Antigestagens [7]
A61P   5/38  \	1	1	4C201	A61P   5/38	1041	եۥˤµΤΤΡΣ	of the suprarenal hormones [7]
A61P   5/40  \	2	2	4C201	A61P   5/40	297	ۼɡ㡥ɥƥ󡨹ۼɤγΰΣ	Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids [7]
A61P   5/42  \	2	2	4C201	A61P   5/42	213	ۼɤγ򸺾ǤޤϤɹΡΣ	for decreasing, blocking or antagonising the activity of mineralocorticosteroids [7]
A61P   5/44  \	2	2	4C201	A61P   5/44	225	ɡɤγΣ	Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids [7]
A61P   5/46  \	2	2	4C201	A61P   5/46	170	ɤγ򸺾ǤޤϤɹΡΣ	for decreasing, blocking or antagonising the activity of glucocorticosteroids [7]
A61P   5/48  \	1	1	4C201	A61P   5/48	550	¡ۥˤµΤΤΡΣ	of the pancreatic hormones [7]
A61P   5/50  \	2	2	4C201	A61P   5/50	1533	󥷥γΡΣ	for increasing or potentiating the activity of insulin [7]
A61P   7/00  \	0	0	4C201	A61P   7/00	11618	դޤϺ˦դμμΣ	Drugs for disorders of the blood or the extracellular fluid [7]
A61P   7/02  \	1	1	4C201	A61P   7/02	13481	ȥӥޡŷޡ쾮ĶŽ˳ޡΣ	Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors [7]
A61P   7/04  \	1	1	4C201	A61P   7/04	6007	зޡŷ¥ʺޡ߷ޡϲ˳ޡΣ	Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents [7, 2006.01]
A61P   7/06  \	1	1	4C201	A61P   7/06	7449	ϷޡΣ	Antianaemics [7]
A61P   7/08  \	1	1	4C201	A61P   7/08	1393	ѷ줷礦ήաƩϺޡƩϺޡŲӻˤµμźޡ㡥۴ķ̸åʿ͹ޣУˡΣ	Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock (artificial tears A61P0027040000)[2006.01]
A61P   7/10  \	1	1	4C201	A61P   7/10	3203	ޡǢޡΣ	Antioedematous agents; Diuretics [7]
A61P   7/12  \	1	1	4C201	A61P   7/12	542	Ǣޡ㡥ǢɼźޡʣģȤϣУˡΣ	Antidiuretics, e.g. drugs for diabetes insipidus (ADH A61P 5/10) [7]
A61P   9/00  \	0	0	4C201	A61P   9/00	39310	۴ĴϼμźޡΣ	Drugs for disorders of the cardiovascular system [7]
A61P   9/02  \	1	1	4C201	A61P   9/02	1598	Ū¡ɷϻɷޡ㡥ȯνֺޡ찵ޡΣ	Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives [7]
A61P   9/04  \	1	1	4C201	A61P   9/04	9557	ϺѺޡ㡥ڼ̺ޡźޡΣ	Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure [7]
A61P   9/06  \	1	1	4C201	A61P   9/06	4728	̮ޡΣ	Antiarrhythmics [7]
A61P   9/08  \	1	1	4C201	A61P   9/08	7034	ŪʷɳĥޡΣ	Vasodilators for multiple indications [7]
A61P   9/10  \	1	1	4C201	A61P   9/10	31636	졤ƥư̮ŲɤμŤΤΤΡ㡥󥮥ʡư̮ĥޡڹɡɡǾή㳲¡ư̮šΣ	for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis [7]
A61P   9/10 101 \	2	2	4C201	A61P   9/10	15770	ư̮Ųʣȣߡ	Antiarteriosclerosis
A61P   9/10 103 \	2	2	4C201	A61P   9/10	5762	ɳĥޡʣȣߡ	Coronary vasodepressor
A61P   9/12  \	1	1	4C201	A61P   9/12	22023	찵ޡΣ	Antihypertensives [7]
A61P   9/14  \	1	1	4C201	A61P   9/14	2967	ݸޡ̮źޡӺٷɰޡΣ	Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers [7]
A61P  11/00  \	0	0	4C201	A61P  11/00	31114	Ƶ۷ϼμΣ	Drugs for disorders of the respiratory system [7]
A61P  11/02  \	1	1	4C201	A61P  11/02	6795	ɡѡ㡥÷ޡΣ	Nasal agents, e.g. decongestants [7]
A61P  11/04  \	1	1	4C201	A61P  11/04	1429	ΤɤµΤΤΡΣ	for throat disorders [7]
A61P  11/06  \	1	1	4C201	A61P  11/06	18392	©Σ	Antiasthmatics [7]
A61P  11/08  \	1	1	4C201	A61P  11/08	3402	ɻٳĥޡΣ	Bronchodilators [7]
A61P  11/10  \	1	1	4C201	A61P  11/10	634	ޡΣ	Expectorants [7]
A61P  11/12  \	1	1	4C201	A61P  11/12	88	ǴϲޡΣ	Mucolytics [7]
A61P  11/14  \	1	1	4C201	A61P  11/14	1739	óΣ	Antitussive agents [7]
A61P  11/16  \	1	1	4C201	A61P  11/16	1118	Ƶ¥ʡΣ	Central respiratory analeptics [7]
A61P  13/00  \	0	0	4C201	A61P  13/00	2872	ǢϼμǢޣУˡΣ	Drugs for disorders of the urinary system (diuretics A61P 7/10) [7]
A61P  13/02  \	1	1	4C201	A61P  13/02	7674	ǢǢϩμźޡ㡥ǢޡΣ	of urine or of the urinary tract, e.g. urine acidifiers [7]
A61P  13/02 105 \	1	1	4C201	A61P  13/02	380	Ǣϩݺޡʣȣߡ	Urinary tractdisinfectant
A61P  13/04  \	1	1	4C201	A61P  13/04	347	ǢоɤΤΤΡΣ	for urolithiasis [7]
A61P  13/06  \	1	1	4C201	A61P  13/06	149	ۺޡΣ	Anti-spasmodics [7]
A61P  13/08  \	1	1	4C201	A61P  13/08	6332	ΩΤΤΡΣ	of the prostate [7]
A61P  13/10  \	1	1	4C201	A61P  13/10	4685	ΤΤΡΣ	of the bladder [7]
A61P  13/12  \	1	1	4C201	A61P  13/12	22797	¡ΤΤΡΣ	of the kidneys [7]
A61P  15/00  \	0	0	4C201	A61P  15/00	15326	ϢμۥϣУˡǥΣ	Drugs for genital or sexual disorders (for disorders of sex hormones A61P 5/24); Contraceptives [7]
A61P  15/00 171 \	1	1	4C201	A61P  15/00	409	ưʪѤǤäơʬवʤΡʣȣߡ	for animals, not classified into 15/02 - 15/18
A61P  15/02  \	1	1	4C201	A61P  15/02	870	紼ΤΤΡΣ	for disorders of the vagina [7]
A61P  15/04  \	1	1	4C201	A61P  15/04	301	¥ʡҵ̡ܼ¥ʤΤΤΡΣ	for inducing labour or abortion; Uterotonics [7]
A61P  15/06  \	1	1	4C201	A61P  15/06	1015	ήɻߡޡΣ	Antiabortive agents; Labour repressants [7]
A61P  15/08  \	1	1	4C201	A61P  15/08	4072	Ϣȼ¥ʤΤΤΡ㡥ҷͶȯޡΣ	for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis [7]
A61P  15/10  \	1	1	4C201	A61P  15/10	3525	ݥƥ󥹤Σ	for impotence [7]
A61P  15/12  \	1	1	4C201	A61P  15/12	1155	ǯ㳲ΤΤΡΣ	for climacteric disorders [7]
A61P  15/14  \	1	1	4C201	A61P  15/14	486	ΤΤΡ㡥ϳΣ	for lactation disorders, e.g. galactorrhoea [7]
A61P  15/14 171 \	2	2	4C201	A61P  15/14	171	ưʪѹ˼ޡʣȣߡ	Drags for antimastitis for animals (Newly added in H11.6)
A61P  15/14 173 \	2	2	4C201	A61P  15/14	55	ưʪѺޡʣȣߡ	galactagogue for animals (Newly added in H11.6)
A61P  15/16  \	1	1	4C201	A61P  15/16	434	ǥΣ	Masculine contraceptives [7]
A61P  15/16 171 \	2	2	4C201	A61P  15/16	27	ưʪѡʣȣߡ	For animals (Newly added in H11.6)
A61P  15/18  \	1	1	4C201	A61P  15/18	891	ǥΣ	Feminine contraceptives [7]
A61P  15/18 171 \	2	2	4C201	A61P  15/18	44	ưʪѡʣȣߡ	For animals (Newly added in H11.6)
A61P  17/00  \	0	0	4C201	A61P  17/00	37375	μΣ	Drugs for dermatological disorders [7]
A61P  17/00 101 \	1	1	4C201	A61P  17/00	2540	ѻݺޡʣȣߡ	disinfectant for skins (Newly added in H11.6)
A61P  17/00 171 \	1	1	4C201	A61P  17/00	278	ưʪѤǤäơʬवʤΡʣȣߡ	Articles for animals which are not assigned to 17/02-17/16 (Newly added in H11.6)
A61P  17/02  \	1	1	4C201	A61P  17/02	14193	硤нסɤΤ褦ʤΤμŤΤΤΡΣ	for treating wounds, ulcers, burns, scars, keloids, or the like [7]
A61P  17/04  \	1	1	4C201	A61P  17/04	5825	ڿޡΣ	Antipruritics [7]
A61P  17/06  \	1	1	4C201	A61P  17/06	16592	ޡΣ	Antipsoriatics [7]
A61P  17/08  \	1	1	4C201	A61P  17/08	1168	ϳޡΣ	Antiseborrheics [7]
A61P  17/10  \	1	1	4C201	A61P  17/10	2940	˥ӺޡΣ	Anti-acne agents [7]
A61P  17/12  \	1	1	4C201	A61P  17/12	673	Ѽϲޡ㡥ܡźޡΣ	Keratolytics, e.g. wart or anti-corn preparations [7]
A61P  17/14  \	1	1	4C201	A61P  17/14	6310	ŤæӾɤΤΤΡΣ	for baldness or alopecia [7]
A61P  17/16  \	1	1	4C201	A61P  17/16	6582	ݼޡݸޡ㡥糰ФΡΣ	Emollients or protectives, e.g. against radiation [7]
A61P  17/18  \	1	1	4C201	A61P  17/18	1396	ɻߺޡ㡥饸ޡɸ뤿ޣѣˡΣ	Antioxidants, e.g. antiradicals (preparations for protection against sunlight A61Q 17/00) [8]
A61P  19/00  \	0	0	4C201	A61P  19/00	6843	ʷϼμźޡΣ	Drugs for skeletal disorders [7]
A61P  19/02  \	1	1	4C201	A61P  19/02	27360	ΤΤΡ㡥ꡤɡΣ	for joint disorders, e.g. arthritis, arthrosis [7]
A61P  19/04  \	1	1	4C201	A61P  19/04	1920	ȿΤΤΡΣ	for non-specific disorders of the connective tissue [7]
A61P  19/06  \	1	1	4C201	A61P  19/06	3745	ޡ㡥ǢɺޡǢ¥ʺޡΣ	Antigout agents, e.g. antihyperuricemic or uricosuric agents [7]
A61P  19/08  \	1	1	4C201	A61P  19/08	7684	ΤΤΡ㡥¡ڡå¡Σ	for bone diseases, e.g. rachitism, Paget's disease [7]
A61P  19/10  \	2	2	4C201	A61P  19/10	10285	Ƥ礦ɤΤΤΡΣ	for osteoporosis [7]
A61P  21/00  \	0	0	4C201	A61P  21/00	14477	ڤޤϿжڷϼμΣ	Drugs for disorders of the muscular or neuromuscular system [7]
A61P  21/02  \	1	1	4C201	A61P  21/02	4203	д˺ޡ㡥³ڹľڻΤΤΡΣ	Muscle relaxants, e.g. for tetanus or cramps [7]
A61P  21/04  \	1	1	4C201	A61P  21/04	6511	žɶ̵ϾɤΤΤΡΣ	for myasthenia gravis [7]
A61P  21/06  \	1	1	4C201	A61P  21/06	259	Ʊ¥ʺޡʥɥУˡΣ	Anabolic agents (androgens A61P 5/26) [7]
A61P  23/00  \	0	0	4C201	A61P  23/00	901	Σ	Anaesthetics [7]
A61P  23/00 171 \	1	1	4C201	A61P  23/00	37	ưʪѡʣȣߡ	for animals
A61P  23/02  \	1	1	4C201	A61P  23/02	784	ɽޡΣ	Local anaesthetics [7]
A61P  25/00  \	0	0	4C201	A61P  25/00	47056	зϼμΣ	Drugs for disorders of the nervous system [7]
A61P  25/02  \	1	1	4C201	A61P  25/02	10010	мΤΤΡΣ	for peripheral neuropathies [7]
A61P  25/04  \	1	1	4C201	A61P  25/04	19011	˺ޡ㡥ԥɡΣ	Centrally acting analgesics, e.g. opioids [7]
A61P  25/06  \	1	1	4C201	A61P  25/06	6166	Ƭ˼źޡΣ	Antimigraine agents [7]
A61P  25/08  \	1	1	4C201	A61P  25/08	9816	Ƥ󤫤ޡڻޡΣ	Antiepileptics; Anticonvulsants [7]
A61P  25/10  \	2	2	4C201	A61P  25/10	202	Ƥ󤫤ȯѡΣ	for petit-mal [7]
A61P  25/12  \	2	2	4C201	A61P  25/12	145	Ƥ󤫤ȯѡΣ	for grand-mal [7]
A61P  25/14  \	1	1	4C201	A61P  25/14	10540	۾ưֺޡ㡥Ƨ¡ͥΣ	for treating abnormal movements, e.g. chorea, dyskinesia [7]
A61P  25/16  \	2	2	4C201	A61P  25/16	16914	ѡ󥽥ޡΣ	Anti-Parkinson drugs [7]
A61P  25/18  \	1	1	4C201	A61P  25/18	13389	ºޡ㡥ȥ󥭥饤¡ʬ¼źޡΣ	Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia [7]
A61P  25/20  \	1	1	4C201	A61P  25/20	9525	̲źޡΣ	Hypnotics; Sedatives [7]
A61P  25/22  \	1	1	4C201	A61P  25/22	9449	԰Σ	Anxiolytics [7]
A61P  25/24  \	1	1	4C201	A61P  25/24	14598	Σ	Antidepressants [7]
A61P  25/26  \	1	1	4C201	A61P  25/26	2774	ʳޡ㡥˥󡤥Σ	Psychostimulants, e.g. nicotine, cocaine [7]
A61P  25/28  \	1	1	4C201	A61P  25/28	37362	źޡ㡥Ǿǽޡǧޡĥϥޡ¤¾ɤμźޡΣ	for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia [7]
A61P  25/30  \	1	1	4C201	A61P  25/30	4396	ѡ¸ɼŤΤΤΡΣ	for treating abuse or dependence [7]
A61P  25/32  \	2	2	4C201	A61P  25/32	2865	륳ѡΣ	Alcohol-abuse [7]
A61P  25/34  \	2	2	4C201	A61P  25/34	1804	ХѡΣ	Tobacco-abuse [7]
A61P  25/36  \	2	2	4C201	A61P  25/36	2432	ԥѡΣ	Opioid-abuse [7]
A61P  27/00  \	0	0	4C201	A61P  27/00	937	дϼμźޡΣ	Drugs for disorders of the senses [7]
A61P  27/02  \	1	1	4C201	A61P  27/02	27764	ѺޡΣ	Ophthalmic agents [7]
A61P  27/04  \	2	2	4C201	A61P  27/04	1479	͹ޡաΣ	Artificial tears; Irrigation solutions [7]
A61P  27/06  \	2	2	4C201	A61P  27/06	6621	㼣źޡƷޡΣ	Antiglaucoma agents or miotics [7]
A61P  27/08  \	2	2	4C201	A61P  27/08	62	ƷޤޤͶޡΣ	Mydriatics or cycloplegics [7]
A61P  27/10  \	2	2	4C201	A61P  27/10	556	Ĵ㳲ΤΤΡ㡥Σ	for accommodation disorders, e.g. myopia [7]
A61P  27/12  \	2	2	4C201	A61P  27/12	2345	ΤΤΡΣ	for cataracts [7]
A61P  27/14  \	2	2	4C201	A61P  27/14	1908	÷ޤޤϹ륮ޡΣ	Decongestants or antiallergics [7]
A61P  27/16  \	1	1	4C201	A61P  27/16	5801	ѺޡΣ	Otologicals [7]
A61P  29/00  \	0	0	4C201	A61P  29/00	55107	˺ޡǮޡɺޡ㡥塼ޥޡ󥹥ƥɷϹΣΣӣɣġϡΣ	Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] [7, 2006.01]
A61P  29/00 101 \	1	1	4C201	A61P  29/00	22511	塼ޥޡʣȣߡ	antirheumatic agents (Newly added in H11.6)
A61P  29/02  \	1	1	4C201	A61P  29/02	1565	ɺѤͭʤΡΣ	without antiinflammatory effect [7]
A61P  31/00  \	0	0	4C201	A61P  31/00	12410	ޡ㡥ݺޡǺޡˡޡΣ	Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics [7]
A61P  31/00 171 \	1	1	4C201	A61P  31/00	407	ưʪѤǤäơʬवʤΡʣȣߡ	Articles for animals which are not assigned to 31/02-31/22 (Newly added in H11.6)
A61P  31/02  \	1	1	4C201	A61P  31/02	769	ɽǺޡΣ	Local antiseptics [7]
A61P  31/04  \	1	1	4C201	A61P  31/04	38400	ݺޡΣ	Antibacterial agents [7]
A61P  31/04 171 \	2	2	4C201	A61P  31/04	1478	ưʪѤǤäơʬवʤΡʣȣߡ	Articles for animals which are not assigned to 31/06, 31/08 (Newly added in H11.6)
A61P  31/06  \	2	2	4C201	A61P  31/06	1946	ˤФΡΣ	for tuberculosis [7]
A61P  31/08  \	2	2	4C201	A61P  31/08	489	餤¤ФΡΣ	for leprosy [7]
A61P  31/10  \	1	1	4C201	A61P  31/10	7685	ݺޡΣ	Antimycotics [7]
A61P  31/12  \	1	1	4C201	A61P  31/12	21899	륹ޡΣ	Antivirals [7]
A61P  31/12 171 \	2	2	4C201	A61P  31/12	953	ưʪѤǤäơʬवʤΡʣȣߡ	Articles for animals which are not assigned to 31/14-31/22 (Newly added in H11.6)
A61P  31/14  \	2	2	4C201	A61P  31/14	7957	ңΣ륹ФΡΣ	for RNA viruses [7]
A61P  31/16  \	3	3	4C201	A61P  31/16	4976	ե륨󥶡饤Υ륹Σ	for influenza or rhinoviruses [7]
A61P  31/18  \	3	3	4C201	A61P  31/18	11043	ȣɣ֤ФΡΣ	for HIV [7]
A61P  31/20  \	2	2	4C201	A61P  31/20	4065	ģΣ륹ФΡΣ	for DNA viruses [7]
A61P  31/22  \	3	3	4C201	A61P  31/22	3606	إڥ륹ФΣ	for herpes viruses [7]
A61P  33/00  \	0	0	4C201	A61P  33/00	3866	ޡΣ	Antiparasitic agents [7]
A61P  33/00 171 \	1	1	4C201	A61P  33/00	957	ưʪѤǤäơʬवʤΡʣȣߡ	Articles for animals which are not assigned to 31/14-31/22 (Newly added in H11.6)
A61P  33/02  \	1	1	4C201	A61P  33/02	2175	ץȥ㡥꡼ޥ˥ȥꥳʥȥץ饺ޡΣ	Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis [7]
A61P  33/02 171 \	2	2	4C201	A61P  33/02	319	ưʪѹޡʣȣߡ	anti-protozoal agents for animals (Newly added in H11.6)
A61P  33/02 173 \	2	2	4C201	A61P  33/02	477	ưʪѹޡʣȣߡ	anti-coccidium agents for animals (Newly added in H11.6)
A61P  33/04  \	2	2	4C201	A61P  33/04	239	᡼кޡΣ	Amoebicides [7]
A61P  33/06  \	2	2	4C201	A61P  33/06	2219	ޥꥢޡΣ	Antimalarials [7]
A61P  33/08  \	2	2	4C201	A61P  33/08	92	ٱΤΤΡΣ	for Pneumocystis carinii [7]
A61P  33/10  \	1	1	4C201	A61P  33/10	1595	ޡΣ	Anthelmintics [7]
A61P  33/12  \	2	2	4C201	A61P  33/12	345	Σ	Schistosomicides [7]
A61P  33/14  \	1	1	4C201	A61P  33/14	1405	γ㡥ޡΣ	Ectoparasiticides, e.g. scabicides [7]
A61P  35/00  \	0	0	4C201	A61P  35/00	111140	ޡΣ	Antineoplastic agents [7]
A61P  35/02  \	1	1	4C201	A61P  35/02	24430	¤ðŪʤΡΣ	specific for leukemia [7]
A61P  35/04  \	1	1	4C201	A61P  35/04	9353	žܤðŪʤΡΣ	specific for metastasis [7]
A61P  37/00  \	0	0	4C201	A61P  37/00	9506	ȱ֤ޤϥ륮μΣ	Drugs for immunological or allergic disorders [7]
A61P  37/02  \	1	1	4C201	A61P  37/02	20173	ȱĴޡΣ	Immunomodulators [7]
A61P  37/04  \	2	2	4C201	A61P  37/04	15692	ȱֻɷޡΣ	Immunostimulants [7]
A61P  37/06  \	2	2	4C201	A61P  37/06	22036	ȱޡ㡥ܿȿȿбΡΣ	Immunosuppressants, e.g. drugs for graft rejection [7]
A61P  37/08  \	1	1	4C201	A61P  37/08	23634	륮ޡʹ©Уѹ륮ޣУˡΣ	Antiallergic agents (antiasthmatic agents A61P 11/06; ophthalmic antiallergics A61P 27/14) [7]
A61P  39/00  \	0	0	4C201	A61P  39/00	1157	ŪݸޤޤϲǺޡΣ	General protective or antinoxious agents [7]
A61P  39/02  \	1	1	4C201	A61P  39/02	3357	ǺޡΣ	Antidotes [7]
A61P  39/04  \	1	1	4C201	A61P  39/04	172	졼ȺޡΣ	Chelating agents [7]
A61P  39/06  \	1	1	4C201	A61P  39/06	4520	ե꡼饸õϹޡΣ	Free radical scavengers or antioxidants [7]
A61P  41/00  \	0	0	4C201	A61P  41/00	1125	ŪˡˤƻѤ㡥ɻߺޤޤϾ˻ʪΣ	Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution [7]
A61P  43/00  \	0	0	4C201	A61P  43/00	7183	롼ףУУŸƤʤüŪΰΣ	Drugs for specific purposes, not provided for in groups A61P 1/00-A61P 41/00 [7]
A61P  43/00 101 \	1	1	4C201	A61P  43/00	3687	ġδﴱ˺Ѥʣȣߡ	Drugs for working on each organ (Newly added in H11.6)
A61P  43/00 105 \	1	1	4C201	A61P  43/00	27292	ȿ˦εǽ˺Ѥʣȣߡ	Drugs for working on functions of tissue cells (Newly added in H11.6)
A61P  43/00 107 \	2	2	4C201	A61P  43/00	6608	˦ޡʣȣߡ	augmenting agents for cells (Newly added in H11.6)
A61P  43/00 111 \	1	1	4C201	A61P  43/00	82840	ʪͰʣȣߡ	Drugs for biologically active substance in vivo (Newly added in H11.6)
A61P  43/00 112 \	2	2	4C201	A61P  43/00	1497	ץ󥸥ͺޡʣȣߡ	prostaglandinsolvent (Newly added in H11.6)
A61P  43/00 113 \	2	2	4C201	A61P  43/00	1962	ҥߥޡʣȣߡ	Anti-histamine agent (Newly added in H11.6)
A61P  43/00 114 \	2	2	4C201	A61P  43/00	1304	ȥ˥ޡʣȣߡ	Anti-serotonin agent (Newly added in H11.6)
A61P  43/00 115 \	2	2	4C201	A61P  43/00	99	֥饸˥ͺޡʣȣߡ	bradykinin solvent(Newly added in H11.6)
A61P  43/00 116 \	2	2	4C201	A61P  43/00	1032	󥮥ƥ󥷥ͺޡʣȣߡ	angiotensin solvent(Newly added in H11.6)
A61P  43/00 117 \	2	2	4C201	A61P  43/00	481	󥿡եͺޡʣȣߡ	interferon solvent (Newly added in H11.6)
A61P  43/00 121 \	1	1	4C201	A61P  43/00	37681	Ϻޡʣȣߡ	synergist (Newly added in H11.6)
A61P  43/00 123 \	1	1	4C201	A61P  43/00	3990	ץɥåʣȣߡ	prodrug (Newly added in H11.6)
A61P  43/00 125 \	1	1	4C201	A61P  43/00	350	Ūˡʣȣߡ	physical therapy (Newly added in H11.6)
A61P  43/00 127 \	2	2	4C201	A61P  43/00	28	ˡѺޡʣȣߡ	Drugs for moxa cautery (Newly added in H11.6)
A61P  43/00 171 \	1	1	4C201	A61P  43/00	996	ưʪѤǤäơ¾ʬवʤΡʣȣߡ	Articles for animals which are not otherwise assigned (Newly added in H11.6)
